Symrise is selling AmeriTerpenes LLC, its U.S.-based terpene ingredients business, to international private equity investor Mutares SE & Co. KGaA, in a move that underscores the company’s broader push to actively reshape its portfolio around its core growth platforms. The transaction, announced and closed simultaneously September 1, positions AmeriTerpenes for continued development under Mutares while allowing Symrise to concentrate management attention and capital on businesses it considers more strategically aligned with its long-term growth agenda.
Symrise and AmeriTerpenes will maintain a long-term commercial relationship, with agreed supply arrangements providing Symrise continued access to renewable, terpene-based raw materials. The companies described the arrangements as creating an enduring industrial partnership supporting both businesses' future growth.
AmeriTerpenes produces renewable terpene ingredients for fragrance, flavor and industrial applications from manufacturing sites in Jacksonville, Florida, and Colonels Island, Georgia. Terpenes are widely used in fragrance and flavor formulations, where demand is increasingly tied to renewable sourcing, consistency and performance. Symrise said the operational carve-out of the business had already been completed, allowing the company to transition to new ownership while maintaining continuity for customers and suppliers.
For Mutares, the deal represents a new platform investment in its chemicals and materials segment and expands its footprint in the strategically important U.S. market. The private equity firm specifically characterized AmeriTerpenes as the type of corporate carve-out suited to its investment model, with plans to support growth in the business and U.S. market.
The divestiture is part of Symrise's One Symrise strategy, which places portfolio management alongside growth and efficiency as one of its three strategic pillars. The company has said the strategy is designed to sustain profitable, sustainable growth by focusing resources on attractive growth opportunities, improving efficiency and actively managing the portfolio. Its 2024 strategy update identified active portfolio management as a key priority, alongside leveraging global scale and building a company-wide innovation ecosystem.
The timing is notable because Symrise has been simultaneously pursuing targeted expansion in areas it views as strategically attractive. In July 2026, for example, it announced plans to acquire Floral Concept to strengthen its position in premium naturals and build a distinctive naturals cluster with Maison Lautier within its fragrance division. In that context, the AmeriTerpenes sale illustrates the other side of the One Symrise strategy: divesting businesses that sit outside the company's highest-priority growth platforms while selectively investing in areas such as premium naturals, fragrance and other higher-growth opportunities.
Financial terms of the AmeriTerpenes transaction were not disclosed. Symrise expects the divestiture to produce a non-cash disposal loss in the mid-double-digit millions of euros, which will be reflected in its 2026 financial statements.
